参考文献/References:
[1] Ferreira C R. The burden of rare diseases[J]. American Journal of Medical Genetics, 2019, 179(06): 885-892.
[2] 《中国罕见病定义研究报告2021》发布[EB/OL].[2025-02-19]. http://health.people.com.cn/n1/2021/0913/c14739-32225468.html.
[3] Chen H, Xiang Y, Tang X, et al. Establishment of a value assessment framework for orphan medicinal products in China[J]. Orphanet Journal of Rare Diseases, 2024, 19(01): 390.
[4] 国家卫生健康委,科技部,工业和信息化部,等.关于公布第二批罕见病目录的通知:国卫医政发〔2023〕26号[A].2023.
[5] 国家卫生健康委,科技部,工业和信息化部,等.关于公布第一批罕见病目录的通知:国卫医发〔2018〕10号[A].2018.
[6] 刘慧玲,许春燕,姚卓君,等.我国罕见病用药保障机制:生产供应、价格保障及医保托底[J].卫生软科学,2025,39(06):80-84.
[7] 侯誉,热伊莎木·艾力,周丽,等.我国儿童罕见病治疗专用药及其医疗保障现状分析[J].医药导报,2025,44(12):1962-1970.
[8] 张森伟,陈非非,李凯渊,等.罕见病专项基金的国际经验及启示[J].医学与社会,2025,38(06):1-8.
[9] 过其祥,刘云鹏,朱珈震,等.基于Orphanet数据库的中国罕见病界定及累积时点患病率测算[J].中国新药杂志,2025,34(01):6-11.
[10] 焦杨,颜建周,李树祥.我国罕见病药物研发现状与技术领域分析——以第二批罕见病目录为例[J].中国新药杂志,2024,33(22):2305-2313.
[11] ICD-10医保版[EB/OL].[2025-08-04].https://code.nhsa.gov.cn/jbzd/
public/dataWesterSearch.html.
[12] 国家卫生健康委办公厅关于印发罕见病诊疗指南(2019年版)的通知[EB/OL].[2024-06-28].http://www.nhc.gov.cn/yzygj/s7659/201902/61d06b4916c348e0810ce1fceb844333.shtml.
[13] 国家卫生健康委办公厅关于印发软骨发育不全等86个罕见病病种诊疗指南(2025年版)的通知[EB/OL].[2025-08-12].https://www.nhc.gov.cn/yzygj/c100068/202507/5b3f41180a42465
eb9eec34597bacaf2.shtml.
[14] 桂俊峰,李京蔚,宋萃.罕见病诊疗现状及发展展望[J].临床医学进展,2024,14(04):681-688.
相似文献/References:
[1]胡善联.国内外罕见病的保障政策研究[J].卫生经济研究,2018,(05):3.
[2]陈馨仪,符 晓,王安石,等.罕见病患者治疗及保障研究[J].卫生经济研究,2020,(09):40.
CHEN Xin-yi,FU Xiao,WANG An-shi,et al.Research on the Treatment and Guarantee of Patients with Rare Diseases[J].Journal Press of Health Economics Research,2020,(05):40.
[3]王子琪,闵连星,田兴军,等.我国罕见病医保政策的现状及优化路径[J].卫生经济研究,2021,38(11):22.
WANG Zi-qi,MIN Lian-xing,TIAN Xing-jun,et al.The Situation and Optimization Path of Medical Insurance Policy for Rare Diseases in China[J].Journal Press of Health Economics Research,2021,38(05):22.
[4]李奕昊,唐贵忠.罕见病用药可负担性评价及医保政策研究[J].卫生经济研究,2022,39(4):53.
LI Yi-hao,TANG Gui-zhong.Affordability Evaluation of Drugs for Rare Diseases and Research on Medical Insurance Policy[J].Journal Press of Health Economics Research,2022,39(05):53.
[5]张永理,张开然.我国罕见病患者医疗保障现状及改进建议[J].卫生经济研究,2023,40(1):53.
ZHANG Yongli,ZHANG Kairan.Medical Security Status and Improvement Suggestions for Patients with Rare Diseases in China[J].Journal Press of Health Economics Research,2023,40(05):53.
[6]朱 坤sup>.中国罕见病保障机制:现状、挑战与建议[J].卫生经济研究,2024,41(01):23.
ZHU Kun.Security Mechanism for Rare Diseases in China: Progress,Problems and Suggestions[J].Journal Press of Health Economics Research,2024,41(05):23.
[7]谭清立,丘丽莹.城市普惠型商业医疗保险比较研究[J].卫生经济研究,2024,41(02):23.
TAN Qingli,QIU Liying.Comparative Study on Urban Inclusive Commercial Medical Insurance[J].Journal Press of Health Economics Research,2024,41(05):23.
[8]王珺琦,殷 悦,唐文熙.医保准入视角下罕见病用药经济价值评估的
难点、方法与建议[J].卫生经济研究,2024,41(09):58.
WANG Junqi,YIN Yue,TANG Wenxi.Difficulties, Methods, and Suggestions for Assessing the Economic Value
of Rare Disease Medications from the Perspective of Health Insurance Access[J].Journal Press of Health Economics Research,2024,41(05):58.
[9]林 星,董田甜.罕见病药品保障模式的国际经验与启示
——以酶替代疗法药品为例[J].卫生经济研究,2024,41(11):54.
LIN Xing,DONG Tiantian.International Experience and Enlightenment of Drug Security Model for Rare Diseases
——Taking Enzyme Replacement Therapy Drugs as an Example[J].Journal Press of Health Economics Research,2024,41(05):54.
[10]沈杨阳.中国罕见病问题及综合保障机制研究[J].卫生经济研究,2024,41(12):1.
SHEN Yangyang.Study on the Problems of Rare Diseases and Comprehensive Protection Mechanisms in China[J].Journal Press of Health Economics Research,2024,41(05):1.